Can Fulcrum Therapeutics Inc. (FULC) Remain Competitive? – News Heater
Home  »  Trending   »  Can Fulcrum Therapeutics Inc. (FULC) Remain Compet...

Can Fulcrum Therapeutics Inc. (FULC) Remain Competitive?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Fulcrum Therapeutics Inc. (NASDAQ:FULC) went up by 1.33% from its latest closing price compared to the recent 1-year high of $33.10. The company’s stock price has collected -12.79% of loss in the last five trading sessions. Press Release reported on 11/17/21 that Fulcrum Therapeutics(R) Appoints Sonja L. Banks to its Board of Directors

Is It Worth Investing in Fulcrum Therapeutics Inc. (NASDAQ :FULC) Right Now?

Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Fulcrum Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The average price from analysts is $35.43, which is $20.22 above the current price. FULC currently public float of 27.24M and currently shorts hold a 7.58% ratio of that float. Today, the average trading volume of FULC was 560.86K shares.

FULC’s Market Performance

FULC stocks went down by -12.79% for the week, with a monthly drop of -35.36% and a quarterly performance of -42.41%, while its annual performance rate touched 42.42%. The volatility ratio for the week stands at 6.68% while the volatility levels for the past 30 days are set at 6.85% for Fulcrum Therapeutics Inc.. The simple moving average for the period of the last 20 days is -21.33% for FULC stocks with a simple moving average of -3.22% for the last 200 days.

Analysts’ Opinion of FULC

Many brokerage firms have already submitted their reports for FULC stocks, with Morgan Stanley repeating the rating for FULC by listing it as a “Overweight.” The predicted price for FULC in the upcoming period, according to Morgan Stanley is $34 based on the research report published on August 11th of the current year 2021.

Credit Suisse, on the other hand, stated in their research note that they expect to see FULC reach a price target of $26. The rating they have provided for FULC stocks is “Outperform” according to the report published on April 26th, 2021.

Credit Suisse gave a rating of “Outperform” to FULC, setting the target price at $26 in the report published on March 22nd of the current year.

FULC Trading at -36.06% from the 50-Day Moving Average

After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.04% of loss for the given period.

Volatility was left at 6.85%, however, over the last 30 days, the volatility rate increased by 6.68%, as shares sank -34.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.60% lower at present.

During the last 5 trading sessions, FULC fell by -12.79%, which changed the moving average for the period of 200-days by +16.91% in comparison to the 20-day moving average, which settled at $18.93. In addition, Fulcrum Therapeutics Inc. saw 29.89% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at FULC starting from Stuart Bryan, who sale 28,000 shares at the price of $23.75 back on Aug 11. After this action, Stuart Bryan now owns 0 shares of Fulcrum Therapeutics Inc., valued at $665,000 using the latest closing price.

Stuart Bryan, the See Remarks of Fulcrum Therapeutics Inc., sale 32,000 shares at $17.50 during a trade that took place back on Aug 10, which means that Stuart Bryan is holding 0 shares at $560,000 based on the most recent closing price.

Stock Fundamentals for FULC

Current profitability levels for the company are sitting at:

  • -811.64 for the present operating margin

The net margin for Fulcrum Therapeutics Inc. stands at -802.66. The total capital return value is set at -78.51, while invested capital returns managed to touch -77.67. Equity return is now at value -53.20, with -44.20 for asset returns.

Based on Fulcrum Therapeutics Inc. (FULC), the company’s capital structure generated 0.02 points at debt to equity in total, while total debt to capital is 0.02.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 26.03, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 6.26 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.47.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

A Lesson to Learn: Colfax Corporation (CFX)

Colfax Corporation (NYSE:CFX) went up by 2.63% from its latest closing price compared to the recent 1-year high of $54.67. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam




Download Free eBook For


100% free. stop anytime no spam